DBV Technologies (NASDAQ:DBVT) Upgraded to Hold by StockNews.com

StockNews.com upgraded shares of DBV Technologies (NASDAQ:DBVTFree Report) from a sell rating to a hold rating in a research report sent to investors on Friday morning.

A number of other research analysts have also recently commented on the company. HC Wainwright reaffirmed a buy rating and set a $10.00 target price on shares of DBV Technologies in a research note on Monday, November 13th. The Goldman Sachs Group cut their target price on DBV Technologies from $1.30 to $1.00 and set a sell rating on the stock in a research note on Thursday, November 2nd.

Get Our Latest Research Report on DBV Technologies

DBV Technologies Stock Performance

DBVT opened at $0.88 on Friday. The stock has a market cap of $170.57 million, a price-to-earnings ratio of -1.58 and a beta of 0.81. The stock’s 50 day moving average price is $0.88 and its 200-day moving average price is $1.12. DBV Technologies has a one year low of $0.65 and a one year high of $2.37.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Commonwealth Equity Services LLC bought a new position in DBV Technologies in the third quarter worth approximately $26,000. BNP Paribas Arbitrage SA bought a new position in DBV Technologies in the second quarter worth approximately $49,000. Citadel Advisors LLC bought a new position in DBV Technologies in the second quarter worth approximately $55,000. OLD Mission Capital LLC grew its stake in DBV Technologies by 243.7% in the first quarter. OLD Mission Capital LLC now owns 30,597 shares of the company’s stock worth $52,000 after purchasing an additional 21,694 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in DBV Technologies during the 4th quarter valued at $54,000. Institutional investors own 23.90% of the company’s stock.

About DBV Technologies

(Get Free Report)

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and eosinophilic esophagitis.

Recommended Stories

Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.